Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease

Movement Disorders

Volumn 27, Issue 6, 2012, Pages 750-753

  Brod, Lissa S ^a,b   Aldred, Jason L ^a,b   Nutt, John G ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Carbidopa; L dopa; Parkinson's disease

Indexed keywords

CARBIDOPA; ENTACAPONE; LEVODOPA; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INJURY; ISCHIALGIA; LOW DRUG DOSE; MALE; OUTPATIENT CARE; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; AREA UNDER CURVE; CARBIDOPA; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84861687128     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24998     Document Type: Article

References (19)

1. Bartholini G, Burkard WP, Pletscher A. Increase of cerebral catecholamines caused by 3, 4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 1967; 215: 852-853.
2. Marsden CD, Parkes JD, Rees JE. A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet 1973; 2: 1459-1462.
3. Markham C, Diamond SG, Treciokas LJ. Carbidopa in Parkinson disease and in nausea and vomiting of levodopa. Arch Neurol 1974; 31: 128-133.
4. Hoehn MM. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study. Arch Neurol 1980; 37: 146-149.
5. Lotti VJ, Porter CC. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors. J Pharmacol Exp Ther 1970; 172: 406-415.
6. Jonkers N, Sarre S, Ebinger G, Michotte Y. Benserazide decreases central AADC activity, extracellular dopamine levels, and levodopa decarboxylation in striatum of the rat. J Neural Transm 2001; 108: 559-570.
7. Carvey PM, Zhao CH, Hendey B, et al. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci 2005; 22: 1158-1168.
8. Kortekaas R, Leenders KL, van Oostrom JCH, Vaalburg W, Bart J, Wilemsen ATM, Hendrickse NH. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005; 57: 176-179.
9. Westin JE, Lindgren HS, Gardi J, Nyengaard JR, Brundin P, Mohapel P, Cenci MA. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3, 4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci 2006; 26: 9448-9461.
10. Astradsson A, Jenkins BG, Choi J, et al. The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates-evidence from in vivo neuroimaging studies. Neurobiol Dis 2009; 35: 348-351.
11. Kaakkola S, Mannisto PT, Nissinen E, Vuorela A, Mantyla R. The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. Acta Neurol Scand 1985; 72: 385-391.
12. Cedarbaum JM, Kutt H, Dhar AK, Watkins S, McDowell FH. Effect of supplemental carbidopa on bioavailability of L-dopa. Clin Neuropharmacol 1986; 9: 153-159.
13. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39.
14. Nutt JG, Gunzler SA, Kirchhoff T, et al. Effects of a NR2B selective NMDA glutamate antagonist, CP-101, 606, on dyskinesia and Parkinsonism. Mov Disord 2008; 23: 1860-1866.
15. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-2685.
16. Tayarani-Binazir KA, Jackson MJ, Fisher R, Zoubiane G, Rose S, Jenner P. The timing of administration, dose dependence, and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset. Eur J Pharmacol 2010; 635: 109-116.
17. Nutt JG, Woodward WR, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 1985; 18: 537-543.
18. Leppert PS, Cortese M, Fix JA. The effects of carbidopa dose and time and route of administration on systemic L-dopa levels in rats. Pharm Res 1988; 5: 587-591.
19. Ward CD, Trombley IK, Calne DB, Kopin IJ. L-Dopa decarboxylation in chronically treated patients. Neurology 1984; 34: 198-201.